Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Hansoh Pharmaceutical Group Company Limited
翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

VOLUNTARY ANNOUNCEMENT

COLLABORATION DEVELOPMENT AGREEMENT WITH AILSYNBIO

The board of directors (the "**Board**") of Hansoh Pharmaceutical Group Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that, on November 13, 2026, Hansoh (Shanghai) Healthtech Co., Ltd.* (翰森(上海)健康科技有限公司), a wholly-owned subsidiary of the Company, entered into a collaboration development agreement (the "**Agreement**") with AilsynBio Limited (昂心生物有限公司) ("**AilsynBio**").

Pursuant to the Agreement, the Company obtains a license to use AilsynBio's AI platform to discover novel oral cyclic peptide drug candidates within the scope of the Agreement. The Company will have the right to select targets, acquire the intellectual property rights in the corresponding programs (the "**Programs**") and lead subsequent development. AilsynBio will be eligible to receive aggregate payments of up to RMB317 million and single-digit royalties on potential future net sales of products developed under the Programs.

AilsynBio is a next-generation AI-native biotechnology company headquartered in Hong Kong, developing innovative therapeutics with a focus on oral cyclic peptides. Combining proprietary AI with experimental validation in a closed-loop discovery platform, AilsynBio aims to expand the reach of peptide medicines and deliver differentiated therapies that address unmet medical needs.

LISTING RULES IMPLICATION

The payments contemplated under the Agreement are expected to be recognized as R&D expenditure of the Company. Assuming that the transactions contemplated under the Agreement constitute "transactions" for the purpose of Chapter 14 of the Listing Rules, as all the applicable percentage ratios in respect of the payments payable under the Agreement are below 5%, the transactions contemplated under the Agreement do not constitute any notifiable transaction under Chapter 14 of the Listing Rules. Furthermore, the transactions contemplated under the Agreement do not constitute any connected transactions of the Company under Chapter 14A of the Listing Rules.

The shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Hong Kong, November 13, 2026

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Ms. Sun Yuan and Dr. Lyu Aifeng as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai, Ms. Yang Dongtao and Mr. Yan Jia as independent non-executive directors.

* *For identification purposes only*